229 related articles for article (PubMed ID: 9816210)
1. Proteases as prognostic markers in cancer.
Duffy MJ
Clin Cancer Res; 1996 Apr; 2(4):613-8. PubMed ID: 9816210
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
Harbeck N; Alt U; Berger U; Krüger A; Thomssen C; Jänicke F; Höfler H; Kates RE; Schmitt M
Clin Cancer Res; 2001 Sep; 7(9):2757-64. PubMed ID: 11555589
[TBL] [Abstract][Full Text] [Related]
3. Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer.
Delebecq TJ; Porte H; Zerimech F; Copin MC; Gouyer V; Dacquembronne E; Balduyck M; Wurtz A; Huet G
Clin Cancer Res; 2000 Mar; 6(3):1086-92. PubMed ID: 10741738
[TBL] [Abstract][Full Text] [Related]
4. Expression, subcellular distribution and plasma membrane binding of cathepsin B and gelatinases in bone metastatic tissue.
Arkona C; Wiederanders B
Biol Chem; 1996 Nov; 377(11):695-702. PubMed ID: 8960370
[TBL] [Abstract][Full Text] [Related]
5. Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients.
Levicar N; Kos J; Blejec A; Golouh R; Vrhovec I; Frkovic-Grazio S; Lah TT
Cancer Detect Prev; 2002; 26(1):42-9. PubMed ID: 12088202
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma.
Häckel CG; Krueger S; Grote HJ; Oshiro Y; Hodges S; Johnston DA; Johnson ME; Roessner A; Ayala AG; Czerniak B
Cancer; 2000 Sep; 89(5):995-1003. PubMed ID: 10964329
[TBL] [Abstract][Full Text] [Related]
7. Possible contribution of active MMP2 to lymph-node metastasis and secreted cathepsin L to bone invasion of newly established human oral-squamous-cancer cell lines.
Kawamata H; Nakashiro K; Uchida D; Harada K; Yoshida H; Sato M
Int J Cancer; 1997 Jan; 70(1):120-7. PubMed ID: 8985100
[TBL] [Abstract][Full Text] [Related]
8. Cathepsin B and other proteases in human colorectal carcinoma.
Jessup JM
Am J Pathol; 1994 Aug; 145(2):253-62. PubMed ID: 8053486
[No Abstract] [Full Text] [Related]
9. The role of cysteine and serine proteases in colorectal carcinoma.
Herszènyi L; Plebani M; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F
Cancer; 1999 Oct; 86(7):1135-42. PubMed ID: 10506696
[TBL] [Abstract][Full Text] [Related]
10. Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer.
Herszènyi L; Plebani M; Carraro P; De Paoli M; Cardin R; Di Mario F; Kusstatscher S; Naccarato R; Farinati F
Am J Gastroenterol; 1997 May; 92(5):843-7. PubMed ID: 9149198
[TBL] [Abstract][Full Text] [Related]
11. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.
Herszényi L; Farinati F; Cardin R; István G; Molnár LD; Hritz I; De Paoli M; Plebani M; Tulassay Z
BMC Cancer; 2008 Jul; 8():194. PubMed ID: 18616803
[TBL] [Abstract][Full Text] [Related]
12. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.
Thomssen C; Oppelt P; Jänicke F; Ulm K; Harbeck N; Höfler H; Kuhn W; Graeff H; Schmitt M
Anticancer Res; 1998; 18(3C):2173-80. PubMed ID: 9703780
[TBL] [Abstract][Full Text] [Related]
13. Characterizing human colorectal carcinomas by proteolytic profile.
Murnane MJ; Shuja S; Del Re E; Cai J; Iacobuzio-Donahue C; Klepeis V
In Vivo; 1997; 11(3):209-16. PubMed ID: 9239513
[TBL] [Abstract][Full Text] [Related]
14. Cysteine and serine proteases in gastric cancer.
Plebani M; Herszènyi L; Cardin R; Roveroni G; Carraro P; Paoli MD; Rugge M; Grigioni WF; Nitti D; Naccarato R
Cancer; 1995 Aug; 76(3):367-75. PubMed ID: 8625115
[TBL] [Abstract][Full Text] [Related]
15. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L.
Goretzki L; Schmitt M; Mann K; Calvete J; Chucholowski N; Kramer M; Günzler WA; Jänicke F; Graeff H
FEBS Lett; 1992 Feb; 297(1-2):112-8. PubMed ID: 1551416
[TBL] [Abstract][Full Text] [Related]
16. [Protease activities in gastric and colon cancer tissues].
Chung SM; Kawai K; Chung HM; Kawamoto K; Tada M
Nihon Shokakibyo Gakkai Zasshi; 1990 Aug; 87(8):1678-85. PubMed ID: 2232301
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer.
Thomssen C; Schmitt M; Goretzki L; Oppelt P; Pache L; Dettmar P; Jänicke F; Graeff H
Clin Cancer Res; 1995 Jul; 1(7):741-6. PubMed ID: 9816040
[TBL] [Abstract][Full Text] [Related]
18. Drug-resistant human laryngeal carcinoma cells have increased levels of cathepsin B.
Osmak M; Svetić B; Gabrijelcić-Geiger D; Skrk J
Anticancer Res; 2001; 21(1A):481-3. PubMed ID: 11299783
[TBL] [Abstract][Full Text] [Related]
19. Protease levels in breast, ovary, and other gynecological tumor tissues: prognostic importance in breast cancer.
Ruppert C; Ehrenforth S; Scharrer I; Halberstadt E
Cancer Detect Prev; 1997; 21(5):452-9. PubMed ID: 9307848
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of tumour cell invasion by protease inhibitors: correlation with the protease profile.
Kolkhorst V; Stürzebecher J; Wiederanders B
J Cancer Res Clin Oncol; 1998; 124(11):598-606. PubMed ID: 9860288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
